MC Monitor: Tolerance and Safety of a Duodenal Probe Monitoring the Microcirculation

Sponsor
Advanced Perfusion Diagnostics (Industry)
Overall Status
Completed
CT.gov ID
NCT02246036
Collaborator
CEISO (Industry)
10
3
1
21
3.3
0.2

Study Details

Study Description

Brief Summary

For Intensive Care Units (ICU) patients, Multiple Organ Dysfunction Syndrome (MODS) is a very common complication yielding high morbidity and mortality. Inadequate regional perfusion of certain organs (gut, kidney, liver, etc) often caused by shock is the main cause of MODS. Current practice uses cardiac output data and blood pressure to manage shock but there are still lacks of information about the regional perfusion. This leads to late MODS diagnostics preventing the implementation of adequate treatment.

Gut perfusion monitoring seems to be a good target to assess the microcirculation but, nowadays, no practical methods or devices are available to measure the gut perfusion, and the current monitoring methods are not specific (CO, BP, OPS-SDF, PCO2, etc).

"MC Monitor" trial is a prospective, multi-center pilot study, enrolling 10 patients.

The probe will be used by intensivists on ICU patients with a risk of shock and requiring mechanical ventilation.

The probe will be placed in the patient with an endoscopic procedure by a gastroenterologist (standard procedure for post-pyloric tubes placement). This procedure will be used to assess the status of the gut mucosa prior to the placement of the APD probe.

Condition or Disease Intervention/Treatment Phase
  • Device: APD probe
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
10 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Clinical Trial to Assess the Tolerance and the Safety of a Duodenal Tube Monitoring the Microcirculation in 10 Critically Ill Patients.
Study Start Date :
Dec 1, 2014
Actual Primary Completion Date :
Sep 1, 2016
Actual Study Completion Date :
Sep 1, 2016

Arms and Interventions

Arm Intervention/Treatment
Experimental: APD probe

Placement of a duodenal probe during 24 hours.

Device: APD probe
The probe will be placed in the patient with an endoscopic procedure by a gastroenterologist (standard procedure for post-pyloric tubes placement).

Outcome Measures

Primary Outcome Measures

  1. Absence of duodenal lesions [24 hours]

    Duodenal lesions are defined as visible alterations of the duodenum.

Secondary Outcome Measures

  1. Signal-to-noise ratio of the APD probe [24 hours]

    The signal is a reflect of the pulsatile flow in the duodenum. This assertion is evaluated thanks to a signal-to-noise ratio of the cardiac frequency in the PPG on other non-filtered signal componants.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • 18 years of age or more,

  • Male or female,

  • ICU patient, on vasoactive amines, under mechanical ventilation,

  • Stable hemodynamic status,

  • Life expectancy expected to exceed 72 hours,

  • Length of ICU stay greater than 5 days,

  • Willing to participate and signed informed consent,

  • Affiliation to the French social security system.

Exclusion Criteria:
  • Pregnant or lactating woman,

  • Ongoing enteral nutrition,

  • Risk of gastrointestinal ischemia,

  • History of pharyngeal surgery surgery, esophageal surgery, radiotherapy of mediastinal area,

  • Known ear-nose-throat malignant disease,

  • Unexplored dysphagia,

  • Known recent gastrointestinal suture,

  • Esophageal varices,

  • Abdominal pain,

  • Unstable cervical fracture,

  • Moribund patient,

  • Active participation in another investigational protocol within the past 30 days,

  • Subject legally protected, under legal guardianship, deprived of his/her liberty by judicial or administrative decision.

Contacts and Locations

Locations

Site City State Country Postal Code
1 CHU Estaing - Service réanimation adultes Clermont-ferrand France 63003
2 Centre Hospitalier Lyon-Sud Lyon France 69310
3 GHU Caremeau - Unité REA Nimes France 30900

Sponsors and Collaborators

  • Advanced Perfusion Diagnostics
  • CEISO

Investigators

  • Principal Investigator: Bernard Allaouchiche, Prof., Hospices Civils de Lyon

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Advanced Perfusion Diagnostics
ClinicalTrials.gov Identifier:
NCT02246036
Other Study ID Numbers:
  • 2014-A00989-38
First Posted:
Sep 22, 2014
Last Update Posted:
Oct 13, 2016
Last Verified:
Oct 1, 2016
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 13, 2016